Gossamer Bio Inc (NASDAQ:GOSS) – Investment analysts at Svb Leerink reduced their Q1 2019 earnings per share (EPS) estimates for shares of Gossamer Bio in a report released on Tuesday, March 26th, according to Zacks Investment Research. Svb Leerink analyst J. Schwartz now forecasts that the company will post earnings of ($0.60) per share for the quarter, down from their prior forecast of ($0.34). Svb Leerink has a “Outperform” rating and a $30.00 price objective on the stock. Svb Leerink also issued estimates for Gossamer Bio’s Q2 2019 earnings at ($0.65) EPS, Q3 2019 earnings at ($0.69) EPS, Q4 2019 earnings at ($0.73) EPS, FY2019 earnings at ($2.67) EPS, FY2020 earnings at ($2.90) EPS, FY2021 earnings at ($3.12) EPS, FY2022 earnings at ($3.53) EPS and FY2023 earnings at ($3.65) EPS.
GOSS has been the subject of several other research reports. Leerink Swann started coverage on shares of Gossamer Bio in a research report on Tuesday, March 5th. They set an “outperform” rating for the company. Bank of America started coverage on shares of Gossamer Bio in a report on Tuesday, March 5th. They issued a “buy” rating and a $30.00 target price for the company. Evercore ISI started coverage on shares of Gossamer Bio in a report on Tuesday, March 5th. They issued an “outperform” rating and a $30.00 target price for the company. Finally, Barclays started coverage on shares of Gossamer Bio in a report on Tuesday, March 5th. They issued an “overweight” rating and a $27.00 target price for the company. Five investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average price target of $29.25.
In other Gossamer Bio news, CFO Bryan Giraudo acquired 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 12th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $96,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Russell J. Cox acquired 7,200 shares of the company’s stock in a transaction that occurred on Tuesday, February 12th. The stock was acquired at an average price of $16.00 per share, with a total value of $115,200.00. The disclosure for this purchase can be found here. Insiders bought 14,750 shares of company stock valued at $236,000 in the last three months.
Gossamer Bio Company Profile
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.
Recommended Story: Moving Average Convergence Divergence (MACD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.